CCM
VRTX icon

Cinctive Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cinctive Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25,000
Closed -$10.2M – 513
2023
Q4 		$10.2M Buy
+25,000
New +$9.24M 0.68% 37

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cinctive Capital Management's VRTX Position: Q2 2026 in Review

Cinctive Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 429% in Q2 2026, buying an estimated $9.6M and bringing the position to 26,712 shares worth $13.3M. The position accounts for 0.49% of the portfolio, ranked #55.

Cinctive Capital Management first reported a position in VRTX in Q4 2019 and has held it in 9 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Cinctive Capital Management held 26,712 shares of Vertex Pharmaceuticals worth $13.3M as of Q2 2026.
  • Cinctive Capital Management bought 21,663 Vertex Pharmaceuticals shares in Q2 2026, an estimated $9.6M.
  • Vertex Pharmaceuticals made up 0.49% of Cinctive Capital Management's portfolio in Q2 2026, its #55 holding.
  • Cinctive Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 9 quarters since.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.